Trial Profile
A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 23 May 2022
Price :
$35
*
At a glance
- Drugs GSK-3368715 (Primary)
- Indications Adenocarcinoma; Bladder cancer; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 11 Mar 2021 Status changed from recruiting to completed.
- 03 Jun 2020 Planned End Date changed from 20 Jun 2022 to 20 Jul 2022.
- 03 Jun 2020 Planned primary completion date changed from 20 Jun 2022 to 20 Jul 2022.